Unimodal Polyether Composition for Bulk Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional multibranched polyoxyalkylene derivatives used to modify bulk drugs, polypeptides, bioactive proteins, and enzymes result in insufficient formulation stability and over-time stability of drug efficacy.
Innovation Solution
A polyether composition with a unimodal molecular weight distribution, a weight average to number average molecular weight ratio of 1.20 or less, and containing a compound with m=1 in an amount of 90 wt % or more, where the oxyalkylene groups are preferably oxyethylene, and the polyether is used as a raw material or pharmaceutical additive to enhance stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multibranched polyoxyalkylene derivatives are used to modify bulk drugs, then the drugs can be formulated, but the formulation stability and over-time stability of drug efficacy are insufficient
Solution Approach 1:
The patent applies parameter changes by strictly controlling the molecular weight distribution parameters of polyoxyalkylene compounds. Specifically, it requires a unimodal distribution with Mw/Mn ratio of 1.20 or less and dominant presence of compounds with m=1 (90 wt% or more). This precise parameter control transforms the polyoxyalkylene compound from a conventional modifier with variable properties to a controlled reagent that ensures consistent formulation stability and drug efficacy over time.
2Reliability
If conventional polyoxyalkylene compounds are used, then various pharmaceutical functions can be achieved, but the over-time stability of drug efficacy is insufficient
Solution Approach 1:
The patent implements parameter changes by establishing strict molecular weight control parameters: unimodal distribution, Mw/Mn ≤ 1.20, and m=1 compounds comprising 90 wt% or more. These precise parameter specifications transform the manufacturing process from conventional polyoxyalkylene production to a precision-controlled process that ensures consistent drug efficacy stability over time.
Solution Approach 2:
The patent applies preliminary action by pre-establishing the optimal molecular weight distribution characteristics before the actual drug formulation process. The polyoxyalkylene compounds are pre-selected and pre-characterized with specific unimodal distributions and m=1 dominance, ensuring that when used in drug modification, they will provide the desired stability without requiring further adjustment during formulation.
3Reliability
If multibranched polyoxyalkylene derivatives are used for drug modification, then drug delivery systems can be created, but formulation stability is insufficient
Solution Approach 1:
The patent resolves the contradiction between formulation stability and structural complexity by changing the key parameter from multibranched structure to linear structure with m=1 dominance. This parameter change simplifies the molecular architecture while simultaneously improving formulation stability, demonstrating that simpler structures with controlled parameters can outperform complex multibranched variants.
Data Source
AI summary
The present invention provides a raw material for bulk drugs and a pharmaceutical additive which provide excellent formulation stability and excellent over-time stability of drug efficacy when used to modify a bulk drug, a polypeptide, a bioactive protein, an enzyme, and the like. The present invention relates to a raw material for bulk drugs or a pharmaceutical additive, containing: a polyether composition (A) represented by formula (1), wherein the polyether composition (A) has a unimodal molecular weight distribution, the polyether composition (A) has a ratio (Mw/Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) of 1.20 or less, and the polyether composition (A) contains a compound in which m is 1 in formula (1) in an amount of 90 wt % or more based on the weight of the polyether composition (A), in formula (1), OR1, R2O, R3O, and R4O are each independently a C2-C8 oxyalkylene group; when each of these moieties exists in the plural number, each OR1, each R2O, each R3O, and each R4O may be the same as or different from each other; these moieties may be bonded randomly or in block; a, b, c, and d are each independently an integer of 50 to 1200; X1 to X4 are each independently a hydrogen atom, a substituent represented by formula (2), or a substituent represented by formula (3); and m is an integer of 1 to 10.